1. Use of medications that are contraindicated with lopinavir/ritonavir, Hydroxychloroquine/ Chloroquine and that cannot be replaced or stopped <br/ >4. Physicianâ??s decision that participation in the trial is not in patientsâ?? best interest, or any condition that does not allow the protocol to be followed safely <br/ >5. Patient already on antiretroviral therapy with Lopinavir-Ritonavir based regimen or on Hydroxychloroquine/Chloroquine <br/ >6. Any known contraindication to test drugs such as retinopathy and QT prolongation <br/ >7. Known allergic reaction to Lopinavir-ritonavir, Hydroxychloroquine/ Chloroquine <br/ >8. Pregnant or breastfeeding females <br/ >9. Receipt of any experimental treatment for 2019-nCoV (off-label, compassionate use, or trial related) within 30 days prior to participation in the present study <br/ >

1. Use of medications that are contraindicated with lopinavir/ritonavir, Hydroxychloroquine/ Chloroquine and that cannot be replaced or stopped <br/ >4. Physicianâ??s decision that participation in the trial is not in patientsâ?? best interest, or any condition that does not allow the protocol to be followed safely <br/ >5. Patient already on antiretroviral therapy with Lopinavir-Ritonavir based regimen or on Hydroxychloroquine/Chloroquine <br/ >6. Any known contraindication to test drugs such as retinopathy and QT prolongation <br/ >7. Known allergic reaction to Lopinavir-ritonavir, Hydroxychloroquine/ Chloroquine <br/ >8. Pregnant or breastfeeding females <br/ >9. Receipt of any experimental treatment for 2019-nCoV (off-label, compassionate use, or trial related) within 30 days prior to participation in the present study <br/ >

N/A

N/A

1. Use of medications that are contraindicated with lopinavir/ritonavir, Hydroxychloroquine/ Chloroquine and that cannot be replaced or stopped <br/ >4. Physicianâ??s decision that participation in the trial is not in patientsâ?? best interest, or any condition that does not allow the protocol to be followed safely <br/ >5. Patient already on antiretroviral therapy with Lopinavir-Ritonavir based regimen or on Hydroxychloroquine/Chloroquine <br/ >6. Any known contraindication to test drugs such as retinopathy and QT prolongation <br/ >7. Known allergic reaction to Lopinavir-ritonavir, Hydroxychloroquine/ Chloroquine <br/ >8. Pregnant or breastfeeding females <br/ >9. Receipt of any experimental treatment for 2019-nCoV (off-label, compassionate use, or trial related) within 30 days prior to participation in the present study <br/ >

1. Use of medications that are contraindicated with lopinavir/ritonavir, Hydroxychloroquine/ Chloroquine and that cannot be replaced or stopped <br/ >4. Physicianâ??s decision that participation in the trial is not in patientsâ?? best interest, or any condition that does not allow the protocol to be followed safely <br/ >5. Patient already on antiretroviral therapy with Lopinavir-Ritonavir based regimen or on Hydroxychloroquine/Chloroquine <br/ >6. Any known contraindication to test drugs such as retinopathy and QT prolongation <br/ >7. Known allergic reaction to Lopinavir-ritonavir, Hydroxychloroquine/ Chloroquine <br/ >8. Pregnant or breastfeeding females <br/ >9. Receipt of any experimental treatment for 2019-nCoV (off-label, compassionate use, or trial related) within 30 days prior to participation in the present study <br/ >